TR201900227T4 - İnsan tümör nekroz faktörü alfa için özgünlüğü olan antikor molekülleri ve bunların kullanımı. - Google Patents

İnsan tümör nekroz faktörü alfa için özgünlüğü olan antikor molekülleri ve bunların kullanımı. Download PDF

Info

Publication number
TR201900227T4
TR201900227T4 TR2019/00227T TR201900227T TR201900227T4 TR 201900227 T4 TR201900227 T4 TR 201900227T4 TR 2019/00227 T TR2019/00227 T TR 2019/00227T TR 201900227 T TR201900227 T TR 201900227T TR 201900227 T4 TR201900227 T4 TR 201900227T4
Authority
TR
Turkey
Prior art keywords
specificity
necrosis factor
tumor necrosis
antibody molecules
human tumor
Prior art date
Application number
TR2019/00227T
Other languages
English (en)
Turkish (tr)
Inventor
Singh Athwal Diljeet
Thomas Brown Derek
Neil Charles Weir Andrew
George Popplewell Andrew
Paul Chapman Andrew
John King David
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201900227(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of TR201900227T4 publication Critical patent/TR201900227T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
TR2019/00227T 2000-06-06 2001-06-05 İnsan tümör nekroz faktörü alfa için özgünlüğü olan antikor molekülleri ve bunların kullanımı. TR201900227T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products

Publications (1)

Publication Number Publication Date
TR201900227T4 true TR201900227T4 (tr) 2019-02-21

Family

ID=9893121

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00227T TR201900227T4 (tr) 2000-06-06 2001-06-05 İnsan tümör nekroz faktörü alfa için özgünlüğü olan antikor molekülleri ve bunların kullanımı.

Country Status (42)

Country Link
US (4) US7012135B2 (OSRAM)
EP (4) EP2230308B1 (OSRAM)
JP (3) JP4064812B2 (OSRAM)
KR (1) KR20020047097A (OSRAM)
CN (1) CN1289671C (OSRAM)
AP (1) AP2092A (OSRAM)
AR (1) AR033978A1 (OSRAM)
AT (1) ATE451460T1 (OSRAM)
AU (1) AU783756B2 (OSRAM)
BE (1) BE2010C019I2 (OSRAM)
BG (1) BG66072B1 (OSRAM)
BR (2) BRPI0106682B8 (OSRAM)
CA (2) CA2380298C (OSRAM)
CY (6) CY1109889T1 (OSRAM)
CZ (1) CZ300737B6 (OSRAM)
DE (3) DE122010000027I1 (OSRAM)
DK (4) DK1287140T3 (OSRAM)
EC (1) ECSP024210A (OSRAM)
ES (5) ES2337763T3 (OSRAM)
FR (1) FR10C0015I2 (OSRAM)
GB (2) GB0013810D0 (OSRAM)
HU (4) HU230561B1 (OSRAM)
IL (3) IL147992A0 (OSRAM)
IS (2) IS2808B (OSRAM)
LT (1) LT2308975T (OSRAM)
LU (1) LU91674I2 (OSRAM)
MX (1) MXPA01013440A (OSRAM)
MY (1) MY136603A (OSRAM)
NL (1) NL300982I9 (OSRAM)
NO (4) NO334808B1 (OSRAM)
NZ (1) NZ516596A (OSRAM)
OA (1) OA12282A (OSRAM)
PE (1) PE20020292A1 (OSRAM)
PL (2) PL212738B1 (OSRAM)
PT (4) PT3059314T (OSRAM)
RU (1) RU2303604C2 (OSRAM)
SI (3) SI2230308T1 (OSRAM)
SK (1) SK288343B6 (OSRAM)
TR (1) TR201900227T4 (OSRAM)
TW (2) TWI316088B (OSRAM)
WO (1) WO2001094585A1 (OSRAM)
ZA (1) ZA200200097B (OSRAM)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2003225900A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Antibody disulfide isomers, use thereof, and methods of analyzing same
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
EP2371392B1 (en) 2002-05-02 2015-07-08 Wyeth Holdings LLC Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
ES2370710T3 (es) 2002-05-28 2011-12-22 Ucb Pharma, S.A. ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
PL213925B1 (pl) * 2002-07-19 2013-05-31 Abbott Biotech Ltd Przeciwcialo anty-TNFα lub jego czesc wiazaca antygen, ich zastosowanie oraz zestaw
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CN101899106A (zh) 2002-10-29 2010-12-01 阿纳福公司 三聚细胞因子的三聚结合蛋白
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1585768A2 (en) * 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004074345A2 (en) * 2003-02-19 2004-09-02 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
PL1639011T3 (pl) * 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
ATE353969T1 (de) * 2003-08-13 2007-03-15 Sandoz Ag Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide
ES2391457T3 (es) * 2003-08-13 2012-11-26 Sandoz Ag Procedimiento para la purificación de polipéptidos recombinantes
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
US7645450B2 (en) * 2004-12-29 2010-01-12 Yuhan Corporation Humanized antibody specific for tumor necrosis factor-alpha
KR20150055116A (ko) 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
EP1888644A1 (en) * 2005-06-01 2008-02-20 Micromet AG Anti-il2 antibodies
US8067547B2 (en) * 2005-06-07 2011-11-29 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting TNFα
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
CA2648582C (en) * 2006-04-07 2016-12-06 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP5452236B2 (ja) * 2007-03-02 2014-03-26 ファーナム・カンパニーズ・インコーポレーテッド ロウ様物質を用いた徐放性組成物
WO2008153997A1 (en) * 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
WO2009026274A1 (en) * 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
AU2009212079B2 (en) * 2008-02-05 2012-08-30 Delenex Therapeutics Ag Antigen-binding polypeptides against cartilage degeneration
JP5766598B2 (ja) * 2008-05-07 2015-08-19 アーゴス セラピューティクス インコーポレイテッド ヒトインターフェロン−αに対するヒト化抗体
CA2728004C (en) 2008-06-25 2022-05-24 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
EP3858854A1 (en) * 2008-06-25 2021-08-04 Novartis AG Stable and soluble antibodies inhibiting tnf
WO2009155724A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
DK2993231T3 (en) 2009-09-24 2018-10-22 Ucb Biopharma Sprl Bacterial strain for recombinant protein expression with protease-low DEGP-retaining chaperone activity and deactivated Tsp and ptr genes
WO2011050242A1 (en) 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) * 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
WO2011109662A1 (en) 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
CA2795734A1 (en) 2010-04-07 2011-10-13 Abbvie Inc. Tnf-.alpha. binding proteins
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JP6175428B2 (ja) 2011-06-01 2017-08-02 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 細菌のポリシストロン性発現系
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
HRP20180226T1 (hr) 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
EP2758512B1 (en) 2011-09-23 2018-05-09 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
RU2653757C2 (ru) 2011-09-23 2018-05-14 Интрексон Актобиотикс Н.В. Модифицированные грамположительные бактерии и их применение
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US10113002B2 (en) 2012-08-13 2018-10-30 Genentech, Inc. Anti-jagged antibodies and methods of use
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
IL252712B2 (en) 2014-12-22 2024-04-01 UCB Biopharma SRL Method for protein production
EP3341021A4 (en) * 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2760997C2 (ru) 2016-01-14 2021-12-02 Интрексон Актобиотикс Н.В. Композиции и способы для лечения диабета 1 типа
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
BR112018074922B1 (pt) * 2016-06-02 2022-10-25 Abbvie Inc Compostos agonistas de receptores de glucocorticoides, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20200095477A (ko) 2017-12-01 2020-08-10 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
US20220127350A1 (en) 2019-01-31 2022-04-28 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240226295A9 (en) 2021-02-15 2024-07-11 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
JP2024534603A (ja) 2021-09-24 2024-09-20 エックスブレイン バイオファーマ エービー 組換えタンパク質を発現させるためのｄｎａ構築物及び宿主細胞
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
CN120225181A (zh) 2022-09-30 2025-06-27 延伸生物科学股份有限公司 长效甲状旁腺激素
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ATE183513T1 (de) * 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
CA2218522A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CA2297692A1 (en) * 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
EP1287140A1 (en) 2003-03-05
PE20020292A1 (es) 2002-05-08
AR033978A1 (es) 2004-01-21
IS3016B (is) 2019-10-15
HUS1700013I1 (hu) 2017-08-28
LT2308975T (lt) 2016-11-10
CA2707766C (en) 2013-05-21
PT2308975T (pt) 2016-11-14
SI2230308T1 (sl) 2013-06-28
EP2308975B1 (en) 2016-08-10
JP2007105043A (ja) 2007-04-26
FR10C0015I2 (fr) 2011-12-30
US20030026805A1 (en) 2003-02-06
JP4476989B2 (ja) 2010-06-09
HU230561B1 (hu) 2016-12-28
WO2001094585A1 (en) 2001-12-13
AU783756B2 (en) 2005-12-01
AU6051101A (en) 2001-12-17
TW200817430A (en) 2008-04-16
NO341218B1 (no) 2017-09-11
CY2019018I1 (el) 2020-05-29
GB0128386D0 (en) 2002-01-16
DE60140738D1 (de) 2010-01-21
IL147992A0 (en) 2002-09-12
CA2380298A1 (en) 2001-12-13
PL353960A1 (en) 2003-12-15
EP2308975A1 (en) 2011-04-13
DK3059314T3 (en) 2019-02-18
CN1383450A (zh) 2002-12-04
BRPI0106682B8 (pt) 2021-05-25
CA2380298C (en) 2010-09-28
AP2002002690A0 (en) 2002-12-31
HUP0202346A2 (en) 2002-10-28
US7186820B2 (en) 2007-03-06
PT1287140E (pt) 2010-03-08
CY2010011I2 (el) 2012-01-25
HK1051385A1 (en) 2003-08-01
JP2003535591A (ja) 2003-12-02
EP2230308A1 (en) 2010-09-22
CZ300737B6 (cs) 2009-07-29
NO2014026I2 (no) 2018-02-14
HUP1600016A2 (en) 2002-10-28
DK1287140T3 (da) 2010-04-19
FR10C0015I1 (OSRAM) 2010-04-16
AP2092A (en) 2010-02-28
ECSP024210A (es) 2002-05-23
HUP1600483A2 (OSRAM) 2002-10-28
CY1109889T1 (el) 2012-01-25
SK288343B6 (sk) 2016-04-01
ES2230975A1 (es) 2005-05-01
BRPI0106682B1 (pt) 2020-10-13
EP1287140B1 (en) 2009-12-09
CY1121173T1 (el) 2020-05-29
EP3059314B1 (en) 2018-10-24
IL195085A0 (en) 2009-08-03
PL218516B1 (pl) 2014-12-31
EP3059314A1 (en) 2016-08-24
ES2600080T3 (es) 2017-02-07
BR0106682A (pt) 2002-05-14
MY136603A (en) 2008-10-31
DK2230308T3 (da) 2013-05-06
CN1289671C (zh) 2006-12-13
SI2308975T1 (sl) 2016-11-30
SI1287140T1 (sl) 2010-04-30
HU230669B1 (hu) 2017-07-28
PL212738B1 (pl) 2012-11-30
PT2230308E (pt) 2013-05-03
CY2019018I2 (el) 2020-05-29
US7977464B2 (en) 2011-07-12
ATE451460T1 (de) 2009-12-15
CY1118220T1 (el) 2017-06-28
HUP0202346A3 (en) 2004-11-29
NL300982I1 (OSRAM) 2019-05-01
US20080269465A1 (en) 2008-10-30
CZ2002837A3 (cs) 2002-05-15
CY1114143T1 (el) 2016-07-27
ES2707714T3 (es) 2019-04-04
US7402662B2 (en) 2008-07-22
GB2366800B (en) 2005-01-19
PT3059314T (pt) 2019-02-01
NO334808B1 (no) 2014-06-02
JP5185143B2 (ja) 2013-04-17
JP2009171966A (ja) 2009-08-06
NZ516596A (en) 2004-07-30
OA12282A (en) 2006-05-11
KR20020047097A (ko) 2002-06-21
MXPA01013440A (es) 2003-09-04
JP4064812B2 (ja) 2008-03-19
IL147992A (en) 2009-06-15
US20060233800A1 (en) 2006-10-19
PL399351A1 (pl) 2012-12-17
DK2308975T3 (da) 2016-10-31
US20020151682A1 (en) 2002-10-17
IS2808B (is) 2012-09-15
BE2010C019I2 (OSRAM) 2020-08-20
TWI353358B (en) 2011-12-01
SK3152002A3 (en) 2002-07-02
DE122010000027I1 (de) 2010-08-12
CY2010011I1 (el) 2012-01-25
LU91674I9 (OSRAM) 2019-01-03
NO20160694A1 (no) 2002-04-08
LU91674I2 (fr) 2010-05-31
TWI316088B (en) 2009-10-21
BG106278A (bg) 2002-12-29
NO20020554L (no) 2002-04-08
NO20020554D0 (no) 2002-02-04
BG66072B1 (bg) 2011-01-31
ES2337763T3 (es) 2010-04-29
NL300982I9 (nl) 2019-05-06
DE10192353T1 (de) 2003-05-22
CA2707766A1 (en) 2001-12-13
NO20131316L (no) 2002-04-08
HK1148776A1 (en) 2011-09-16
HU230553B1 (hu) 2016-11-28
GB2366800A (en) 2002-03-20
GB0013810D0 (en) 2000-07-26
US7012135B2 (en) 2006-03-14
IS6217A (is) 2002-01-03
NO339282B1 (no) 2016-11-21
EP2230308B1 (en) 2013-01-23
RU2303604C2 (ru) 2007-07-27
NO2014026I1 (no) 2014-10-23
ZA200200097B (en) 2003-01-06
ES2403217T3 (es) 2013-05-16
ES2230975B2 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
TR201900227T4 (tr) İnsan tümör nekroz faktörü alfa için özgünlüğü olan antikor molekülleri ve bunların kullanımı.
TW200714081A (en) Encoding apparatus, encoding method and program thereof, and decoding apparatus, decoding method and program thereof
MX2021008151A (es) Metodo y aparato de prediccion de bloques de croma.
MX2016000943A (es) Aparato y método para codificar y decodificar una señal de audio con relleno inteligente de separaciones en el dominio espectral.
PH12015501079B1 (en) Method and apparatus for encoding video by using deblocking filtering, and method and apparatus for decoding video by using deblocking filtering
MY154633A (en) Multi-resolution switched audio encoding/decoding scheme
CY1119272T1 (el) Μεθοδος και συσκευη για την κωδικοποιηση βιντεο με αντισταθμιση της τιμης pixel συμφωνα με τις ομαδες pixel, και μεθοδος και συσκευη για την αποκωδικοποιηση βιντεο με τον ιδιο τροπο
MY175855A (en) Method and apparatus for encoding video, and method and apparatus for decoding video
TW200627962A (en) Video coding, decoding and hypothetical reference decoder
MX2009003967A (es) Sistema y método para implementar una administración eficiente de memoria intermedia decodificada en codificación de video de vistas múltiples.
TW200723887A (en) Method and apparatus for weighted prediction for scalable video coding
EA201301072A1 (ru) Антитела против il-23p19 и их применение
TW200625970A (en) Color image encoding and decoding method and apparauts using a correlation between chrominance components
BR0305432A (pt) Método de codificação de imagem e método de decodificação de imagem
CY1121422T1 (el) Διαταξη αποκωδικοποιησης εικονας
MY180135A (en) Nested entropy encoding
MY187111A (en) Method and apparatus for encoding and decoding image by using large transform unit
ATE441905T1 (de) Codierschema für einen ein zeitlich veraenderliches graphikmodell darstellenden datenstrom
MXPA06014105A (es) Metodo y aparato para codificacion y descodificacion sin perdida.
MX2007003063A (es) Codificacion combinada de audio que minimiza la distorsion perceptual.
WO2009037726A1 (ja) 動画像符号化装置および動画像復号装置
MY149236A (en) Picture coding apparatus and picture decoding apparatus
TW200714080A (en) Transcoder and transcoding method operating in a transform domain for video coding schemes possessing different transform kernels
TW200706013A (en) Dynamic image encoding device, dynamic image decoding device, dynamic image encoding method, dynamic image decoding method, dynamic image encoding program, and dynamic image decoding program
PH12021550833A1 (en) Image coding/decoding method, coder, decoder, and storage medium